Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Mammalian cell-cycle control by antimitogenic signals involves p21Cip1/WAF1 (refs 1-4), p27Kip1 (refs 5, 6) and p57Kip2 (refs 7, 8), a family of proteins that bind to and inhibit cyclin-dependent kinases (CDKs) required for initiation of S phase. The protein p21 also binds to the DNA polymerase delta processivity factor, proliferating-cell nuclear antigen (PCNA), and inhibits in vitro PCNA-dependent DNA replication. The CDK and PCNA inhibitory activities of p21 are shown here to be functionally independent and to reside in separate protein domains. The PCNA binding and inhibitory activities, which are not observed with p27 or p57, reside in the C-terminal domain of p21, whereas the CDK inhibitory activity resides in the conserved N-terminal domains of these proteins. When separately overexpressed in mammalian cells, the CDK and PCNA inhibitory domains prevent DNA replication, demonstrating a dual function of p21 as a cell-cycle inhibitor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“P21 functions primarily by binding to and inhibiting CDKs, and in addition, p21 halts the cell cycle by blocking PCNA, which is required for DNA replication.150, 151”
From Census and evaluation of p53 target genes (2017) · cites this paper as [150]
In the citing paper
“P21 functions primarily by binding to and inhibiting CDKs, and in addition, p21 halts the cell cycle by blocking PCNA, which is required for DNA replication.150, 151”
From Census and evaluation of p53 target genes (2017) · cites this paper as [150]
In the citing paper
“While the p21/PCNA ratio was reported to never exceed a 1:1 ratio in cells [37,38], a ratio of at least 10:1 is required to block DNA repair by nucleotide excision repair (NER) in vitro [38,39,40,41].”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [38]
In the citing paper
“While the p21/PCNA ratio was reported to never exceed a 1:1 ratio in cells [37,38], a ratio of at least 10:1 is required to block DNA repair by nucleotide excision repair (NER) in vitro [38,39,40,41].”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [38]
In the citing paper
“When assessing the effect of p21 on PCNA-dependent DNA synthesis in cells, several reports showed a limited or null effect of p21–PCNA interaction on DNA replication [38,45,46,47,48,49,50,51].”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [38]
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A short amino acid sequence able to specify nuclear location
Kalderon, D., Roberts, B. L., Richardson, W. D., & Smith, A. E. (1984) · Cell · doi:10.1016/0092-8674(84)90457-4 · Cited by 2,507
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Self-citationp27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
Matsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J. W., & Elledge, S. J. (1995) · Genes & Development · doi:10.1101/gad.9.6.650 · Cited by 952
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Lee, M. H., Reynisdóttir, I., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.6.639 · Cited by 889
Self-citation
Research works printed but not linked: 1
- Kelman, Z., Naktinis, V. & O'Donnell, M. Meth. Enzym. (in the press).
Cited by
Items 301–400 of 548
Zhou, S., Zhang, Y., Zhou, Z., Jin, H., Hu, C., He, Z., Yu, Z., Ko, K., Yang, T., Zhang, X., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s77071 · Cited by 33
“…in coordination with cyclin E/A. 42 In addition, another key factor, PCNA, also plays an important role in the regulation of the cell cycle; PCNA coordinates cell cycle progression by interacting with several cell cycle-regulating proteins, such as cyclin–CDK complexes 45,46 and p21 Cip1.”
Noureini, S. K., & Wink, M. (2015) · Molecules · doi:10.3390/molecules20033730 · Cited by 30
“It is known that cell division is strongly suppressed by p21 through interaction with proliferating cell nuclear antigen (PCNA) [37] and repression of cyclin-dependent kinase 1 (CDK1) or cell division cycle protein 2 homolog (CDC2), checkpoint kinase 1 (CHEK1) and TERT [38].”
BackgroundOhlson, L. C. E., Koroxenidou, L., & Hällström, I. P. (1998) · Hepatology · doi:10.1002/hep.510270309 · Cited by 30
Rank, K. B., Evans, D. B., & Sharma, S. K. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2648 · Cited by 37
Zang, Y., Tai, Y., Wan, B., & Jia, X. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2758 · Cited by 33
“…of CRMP1 downregulated p53 protein expression in TE2 EC cells. p21-mediated growth inhibition has been attributed to two main activities that depend on two non-overlapping structural domains: the carboxy-terminal PCNA-binding domain and the amino-terminal CDK-cyclin inhibitory domain (33,34).”
A sychnological cell penetrating peptide mimic of p21WAF1/CIP1 is pro-apoptogenic
Baker, R. D., Howl, J., & Nicholl, I. D. (2006) · Peptides · doi:10.1016/j.peptides.2006.12.013 · Cited by 29
“[12,19,22].”
Slíva, D. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.996 · Cited by 29
Corroyer, S., Schittny, J. C., Djonov, V., Burri, P. H., & Clément, A. (2002) · Pediatric Research · doi:10.1203/00006450-200202000-00008 · Cited by 31
p21 cip1 rescues human mesenchymal stem cells from apoptosis induced by low-density culture
van den Bos, C., Silverstetter, S., Murphy, M. J., & Connolly, T. (1998) · Cell and Tissue Research · doi:10.1007/s004410051138 · Cited by 29
“One possible mediator of this event is PCNA and it has been shown that p21 but not p27 can bind to PCNA and inhibit DNA synthesis (Luo et al. 1995) Since we observed an increase in S-phase hMSCs”
BackgroundRelationship between Expression of p21WAF1/CIP1 and Radio resistance in Human Gliomas
Kokunai, T., & Tamaki, N. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00795.x · Cited by 29
Tournier, S., Leroy, D., Goubin, F., Ducommun, B., & Hyams, J. S. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.4.651 · Cited by 30
“Other groups have used different experimental strategies to identify the two binding domains (Chen et al., 1995; Luo et al., 1995; Warbrick et al., 1995).”
Yamamoto, S., Kohsaka, S., & Nakajima, K. (2012) · Glia · doi:10.1002/glia.22291 · Cited by 29
“The CdkI proteins interact with a variety of cyclin/Cdk complexes through a conserved N-terminal domain containing both cyclin- and Cdk-binding sites (Chen et al., 1995; Luo et al., 1995).”
BackgroundMihailidou, C., Papavassiliou, A. G., & Kiaris, H. (2013) · Biochimie · doi:10.1016/j.biochi.2013.11.003 · Cited by 28
Zhang, M., Gan, L., & Ren, G. (2012) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2012007500035 · Cited by 27
Oh, Y.-T., Chun, K. H., Park, B. D., Choi, J., & Lee, S. K. (2007) · APOPTOSIS · doi:10.1007/s10495-007-0066-8 · Cited by 32
“p21 is a cyclin-dependent kinase (CDK) inhibitor that acts as an important cell-cycle regulator via two distinct functional domains: an N-terminal domain (aa 10–80) that functions as a cyclin- and CDK-binding region [1] and a C-terminal domain (aa 139–164) that binds to PCNA and cyclin [2, 3].”
BackgroundSOSTDC1 is down-regulated in non-small cell lung cancer and contributes to cancer cell proliferation
Liu, L., Wu, S., Yang, Y., Cai, J., Zhu, X., Wu, J., Li, M., & Guan, H. (2016) · Cell & Bioscience · doi:10.1186/s13578-016-0091-9 · Cited by 29
“Moreover, p21Cip could directly interfere with DNA replication by inhibiting PCNA [18].”
BackgroundBhowmik, T., Saha, P. P., Sarkar, A., & Gomes, A. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.11.007 · Cited by 27
Identification of Xenopus cyclin-dependent kinase inhibitors, p16Xic2 and p17Xic3
Daniels, M., Dhokia, V., Richard‐Parpaillon, L., & Ohnuma, S. (2004) · Gene · doi:10.1016/j.gene.2004.07.038 · Cited by 27
Target validation and structure–activity analysis of a series of novel PCNA inhibitors
McKillip, K. D., Seibel, W. L., Zhao, D., Lu, S., & Dong, Z. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.115 · Cited by 29
“Several peptides mimicking the PIP-box and APIM have been developed (Luo et al. 1995; Gilljam et al. 2009; Bozza et al. 2012; Muller et al. 2015 | Vol. 3 | Iss.”
InfluentialStaversky, R. J., Watkins, R. H., Wright, T. W., Hernady, E., LoMonaco, M. B., D’Angio, C. T., Williams, J. P., Maniscalco, W. M., & O’Reilly, M. A. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64414-8 · Cited by 31
“It contains two functional domains that can independently inhibit DNA synthesis.(13) The amino-terminal domain binds and inhibits cyclin E/cdk2 kinase activity, which is required for entry into S phase.”
BackgroundRequirement for PCNA and RPA in interstrand crosslink-induced DNA synthesis
Li, L., Peterson, C. A., Zhang, X., & Legerski, R. J. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.6.1424 · Cited by 32
Kawagishi, N., Hashimoto, Y., Takahashi, H., Ishida‐Yamamoto, A., & Iizuka, H. (1998) · Journal of Dermatological Science · doi:10.1016/s0923-1811(98)00024-3 · Cited by 30
“While p21 directly binds to PCNA, inhibiting replicative DNA synthesis [41], it does not interfere with the PCNA-dependent DNA excision repair [44,45].”
BackgroundGomes, A., Giri, B., Alam, A., Mukherjee, S., Bhattacharjee, P., & Gomes, A. (2011) · Toxicon · doi:10.1016/j.toxicon.2011.05.008 · Cited by 27
“The protein p21cip1 binds to the DNA polymerase d processivity factor, proliferating cell nuclear antigen (PCNA) and inhibits PCNA-dependent DNA replication (Luo et al., 1995).”
BackgroundEngineering dynamic cell cycle control with synthetic small molecule-responsive RNA devices
Wei, K. Y., & Smolke, C. D. (2015) · Journal of Biological Engineering · doi:10.1186/s13036-015-0019-7 · Cited by 28
The Temporal Regulation of S Phase Proteins During G1
Grant, G. D., & Cook, J. G. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6955-0_16 · Cited by 34
“DREAM assembly is also facilitated in G0 because cyclin D/CDK4 (low in G0) can phosphorylate p130 to disrupt its incorporation into the DREAM complex (Sandoval et al. 2009).”
BackgroundInfluentialIntegration of the PRB and P53 Cell Cycle Control Pathways
Stewart, C. L., Soria, A. M., & Hamel, P. A. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010615822317 · Cited by 31
“Overexpression of the C-terminal domain of p21 in mammalian cells reduces the fraction of cells found in S phase [183].”
Nakajima, A., Shimizu, S., Moriya, H., & Yamazaki, M. (2003) · Endocrinology · doi:10.1210/en.2003-0158 · Cited by 29
Chuang, L.-C., & Yew, P. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506429200 · Cited by 29
Keblusek, P., Dorsman, J. C., Teunisse, A. F. A. S., Teunissen, H., van der Eb, A. J., & ZANTEMA, A. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-2-381 · Cited by 29
“As a control, the same Western blot was also probed with antibodies against the already identified p21 CIP"/WAF" -binding proteins cdk2 and PCNA (Luo et al., 1995).”
BackgroundMethodInfluentialCalvi, C., Dentelli, P., Pagano, M., Rosso, A., Pegoraro, M., Giunti, S., Garbarino, G. M., Camussi, G., Pegoraro, L., & Brizzi, M. F. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000116864.86607.35 · Cited by 26
Konstantinidou, A. E., Korkolopoulou, P. A., Vassilopoulos, I., Tsenga, A., Thymara, I., Agapitos, E. B., Patsouris, E., & Davaris, P. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00092-6 · Cited by 26
“P21 is transcriptionally activated by wild-type p53 in cells with DNA damage and plays a dual role at the G1 checkpoint interacting independently with cyclin–Cdk complexes and with the DNA polymerase replicating factor PCNA [5,6].”
BackgroundDiabetic LDL inhibits cell-cycle progression via STAT5B and p21waf
Brizzi, M. F., Dentelli, P., Pavan, M., Rosso, A., Gambino, R., Cesaris, M. G. D., Garbarino, G. M., Camussi, G., Pagano, G., & Pegoraro, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci13617 · Cited by 26
Growth Regulation by the E2F and DP Transcription Factor Families
Yamasaki, L. (1998) · Results and problems in cell differentiation · doi:10.1007/978-3-540-69686-5_9 · Cited by 28
Tang, J., Shen, C., & Lu, Y. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9206-7 · Cited by 25
Cell cycle control of eukaryotic DNA replication
Kearsey, S. E., Labib, K. P. M., & Maiorano, D. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)80052-9 · Cited by 24
Mutational analysis of thep21/WAF1/CIP1/SDI1 coding region in human tumor cell lines
Terry, L. A., Boyd, J. A., Alcorta, D. A., Lyon, T., Solomon, G. G., Hannon, G. J., Berchuck, A., Beach, D., & Barrett, J. C. (1996) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199608)16:4<221::aid-mc6>3.0.co;2-i · Cited by 27
Correction: Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival
Zaman, M. S., Shahryari, V., Deng, G., Thamminana, S., Saini, S., Majid, S., Chang, I., Hirata, H., Ueno, K., Yamamura, S., et al. (2012) · PLoS ONE · doi:10.1371/annotation/6662579f-3a41-4bce-9298-9d15f6582ef5 · Cited by 26
Indeglia, A., & Murphy, M. E. (2024) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2024.2344465 · Cited by 32
“Although p53 has been shown to transcriptionally activate other genes involved in G1 arrest such as 14-3-3σ and Killin , p21 remains the dominant p53 target gene that regulates the cell cycle pathway (luo et al. 1995; chen 2016).”
BackgroundMoxley, A. H., & Reisman, D. (2020) · Cell Biochemistry and Function · doi:10.1002/cbf.3590 · Cited by 27
“Furthermore, p21 binds proliferating cell nuclear antigen (PCNA), a protein required for DNA synthesis, and prevents its assembly at the replication fork.(38,40)”
BackgroundKarakas, B., Weeraratna, A. T., Abukhdeir, A. M., Blair, B. G., Konishi, H., Arena, S., Becker, K. G., Wood, W., Argani, P., Marzo, A. M. D., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209540 · Cited by 24
“To determine which regulatory region of p21 was responsible for mediating the repressive effect on IL-1a gene expression, functional/mutational studies were carried out. p21 has been demonstrated to have a number of different functions, including its ability to bind and inhibit CDKs and the auxiliary DNA polymerase d…”
BackgroundInfluentialSanz-Gonzalez, S. M. (2000) · Frontiers in bioscience · doi:10.2741/sanz · Cited by 24
“In addition to its inhibitory effect on CDKs, p21 can also inhibit DNA replication through direct interaction with proliferating cell nuclear antigen (PCNA) (27, 28).”
BackgroundInfluentialInhibition of p21/Waf1/Cip1/Sdi1 Expression by Hepatitis C Virus Core Protein
Yoshida, I., Oka, K., Hidajat, R., Nagano‐Fujii, M., Ishido, S., & Hotta, H. (2001) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2001.tb01303.x · Cited by 24
Yamato, K., Hashimoto, S., Okahashi, N., Ishisaki, A., Nonaka, K., Koseki, T., Kizaki, M., Ikeda, Y., & Nishihara, T. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4876 · Cited by 26
Maga, G., Blanca, G., Shevelev, I., Frouin, I., Ramadan, K., Spadari, S., Villani, G., & Hübscher, U. (2004) · The FASEB Journal · doi:10.1096/fj.04-2268fje · Cited by 23
“The p21protein is induced upon DNA damage, senescence or differentiation of cells, and blocks progression of the cell cycle through its interaction CDKs and PCNA (30, 31).”
Backgroundp16ink4aGene and Hematological Malignancies
Quesnel, B., Preudhomme, C., & Fenaux, P. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609051724 · Cited by 25
Overcoming of Radioresistance in Human Gliomas by p21WAF1/CIP1 Antisense Oligonucleotide
Kokunai, T., Urui, S., Tomita, H., & Tamaki, N. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010645205169 · Cited by 23
“Human p21 cDNA was amplified by PCR using a previously reported method [ 3 ].”
Kapila, Y. L., Wang, S., Dazin, P. F., Tafolla, E., & Mass, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108932200 · Cited by 24
Staalesen, V., Leirvaag, B., Lillehaug, J. R., & Lønning, P. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0796 · Cited by 24
Antiproliferative and Survival Properties of PMA in MCF-7 Breast Cancer Cell
Fortino, V., Torricelli, C., Capurro, E., Sacchi, G., Valacchi, G., & Maioli, E. (2008) · Cancer Investigation · doi:10.1080/07357900701637949 · Cited by 22
“This arrest may be reinforced by the ability of p21 to stop DNA replication by binding to proliferating cell nuclear antigen (PCNA) (28).”
Backgroundp21 (WAF1/CIP1) Is Required for the Mitogenic Response to Intestinal Resection
Stern, L. E., Falcone, R. A., Kemp, C. J., Erwin, C. R., & Warner, B. W. (2000) · Journal of Surgical Research · doi:10.1006/jsre.2000.5834 · Cited by 22
“lication [17].”
Takahashi, A. (2000) · International Journal of Radiation Biology · doi:10.1080/095530000138673 · Cited by 22
Evidence of cellular senescence during the development of estrogen-induced pituitary tumors
Sabatino, M. E., Petiti, J. P., Sosa, L. D. V., Pérez, P. A., Gutiérrez, S., Leimgruber, C., Latini, A., Torres, A. I., & Paul, A. L. D. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0333 · Cited by 28
Kim, C., Lee, J. H., Baek, S. H., Ko, J., Nam, D., & Ahn, K. S. (2017) · Phytotherapy Research · doi:10.1002/ptr.5829 · Cited by 21
“…inhibiting the activities of cyclin E/CDK2 and cyclin D/CDK4 complexes and blocks DNA replication by binding to proliferating cell nuclear antigen (Luo et al., 1995). p53 is important inmulti-cellular organisms,where it regulates the cell cycle and, thus, functions as a tumor suppressor protein…”
BackgroundFan, Q., & Liu, B. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139686 · Cited by 22
“It can block the cell cycle progression through binding to and inhibiting cell cycle promoters such as cyclin-dependent kinases (CDKs) and proliferating cell nuclear antigen (PCNA).(35) Overexpression of p21 has been shown to induce G1 phase arrest and inhibit tumor growth in vitro and in vivo.”
Diabetic LDL inhibits cell-cycle progression via STAT5B and p21waf
Brizzi, M. F., Dentelli, P., Pavan, M., Rosso, A., Gambino, R., Cesaris, M. G. D., Garbarino, G. M., Camussi, G., Pagano, G., & Pegoraro, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213617 · Cited by 21
Regulation of c-Met Expression in Rats with Acute Hepatic Failure
Mizuguchi, T., Kamohara, Y., Hui, T., Neuman, T., Mitaka, T., Demetriou, A. A., & Rózga, J. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6216 · Cited by 20
Huleatt, J. W., Cresswell, J. A., Bottomly, K., & Crispe, I. N. (2003) · Immunology · doi:10.1046/j.1365-2567.2003.01605.x · Cited by 20
Funaoka, K., Shindoh, M., Yamashita, T., Fujinaga, K., Amemiya, A., & Totsuka, Y. (1996) · Cancer Letters · doi:10.1016/s0304-3835(96)04362-5 · Cited by 20
Bao, G. C., Wang, J., & Jong, A. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.05.052 · Cited by 20
Carboxyl-terminal Domain of p27Kip1 Activates CDC2
Üren, A., Jakus, J., de Mora, J. F., Yeudall, W. A., Santos, E., Gutkind, J. S., & Heidaran, M. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.21669 · Cited by 20
Jiao, S., Zheng, X., Yang, X. W., Zhang, J. C., & Wang, L. (2012) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y11-105 · Cited by 21
Mo, Q., Hu, L., Weng, J., Zhang, Y., Zhou, Y., Xu, R., Zuo, Z., Deng, J., Ren, Z., Zhong, Z., et al. (2017) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155417722118 · Cited by 19
“The inhibition of cyclin D1 can induce G1 phase arrest and can result in apoptosis or autophagy.(22,23) Besides, the association of CDK2 with cyclin E/A regulates the G1/S transition and modulates cellular events in the S phase.”
BackgroundVitiello, P. F., Staversky, R. J., Gehen, S. C., Johnston, C. J., Finkelstein, J. N., Wright, T. W., & O’Reilly, M. A. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051162 · Cited by 19
Phylogenetic analysis of archaeal PCNA homologues
Iwai, T., Kurosawa, N., ITOH, Y. H., & Horiuchi, T. (2000) · Extremophiles · doi:10.1007/s007920070005 · Cited by 19
Cloning and functional expression of a degradation-resistant novel isoform of p27Kip1
Hirano, K., Hirano, M., Zeng, Y., Nishimura, J., Hara, K., Muta, K., Nawata, H., & Kanaide, H. (2000) · Biochemical Journal · doi:10.1042/bj3530051 · Cited by 19
Owen, H. C., Ahmed, S. F., & Farquharson, C. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9276-0 · Cited by 20
“activity [17, 29].”
P21, COX-2, and E-cadherin are potential prognostic factors for esophageal squamous cell carcinoma
Lin, Y., Shen, L., Fu, H., Dong, B., Yang, H., Yan, W., Kang, X., Dai, L., Zhou, H., Yang, Y., et al. (2016) · Diseases of the Esophagus · doi:10.1111/dote.12522 · Cited by 21
Silencing of p29 Affects DNA Damage Responses with UV Irradiation
Chu, P., Yang, Y., Lu, Y., Chen, H.-T., Yu, L., & Chang, M.-S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3229 · Cited by 18
Phromnoi, K., Reuter, S., Sung, B., Limtrakul, P., & Aggarwal, B. B. (2010) · PubMed · Cited by 24
Kim, K. M., Cho, H., & Kim, Y. K. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.135 · Cited by 18
Hauck, L., Grothe, D., & Billia, F. (2016) · Peptides · doi:10.1016/j.peptides.2016.07.003 · Cited by 18
Andrés, V. (1998) · Frontiers in bioscience · doi:10.2741/a240 · Cited by 22
Cip/Kip Cell-cycle Inhibitors: A Neuro-oncological Perspective
Mainprize, T. G., Taylor, M. D., Rutka, J. T., & Dirks, P. B. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010671908204 · Cited by 26
“This stretch of 60 amino acids has been shown to be sufficient for CDK inhibition [5,6].”
BackgroundNguyên, V., Candal, E., Sharif, A., Joly, J., & Bourrat, F. (2001) · Developmental Dynamics · doi:10.1002/dvdy.1203 · Cited by 20
“An example, p21CIP1 binds the PCNA (Waga et al., 1994; Chen et al., 1995; Luo et al., 1995).”
BackgroundInfluentialFujigaki, Y., Sun, D. F., Fujimoto, T., Yonemura, K., Morioka, T., Yaoita, E., & Hishida, A. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280100433 · Cited by 18
Mutation and mutagenesis in inherited and acquired human disease
Evans, H. J. (1996) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(95)00201-4 · Cited by 17
BDNF accelerates gene expression in cultured cerebellar granule neurons
Lin, X., Cui, H., & Bulleit, R. F. (1998) · Developmental Brain Research · doi:10.1016/s0165-3806(97)00193-4 · Cited by 17
KLHL4, a novel p53 target gene, inhibits cell proliferation by activating p21
Choi, S., Cho, S.-Y., Song, J.-Y., & Hur, M. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.07.100 · Cited by 19
Bharadwaj, A. G., Goodrich, N. P., McAtee, C. O., Haferbier, K. L., Oakley, G. G., Wahl, J. K., & Simpson, M. A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.01.026 · Cited by 17
“A further explanation for the opposing effects of p21 and p27 upregulation on Hyal1 versus HAS3 transfectants is that these proteins bind to proliferating cell nuclear antigen (PCNA), a DNA polymerase δ processivity factor, thereby blocking DNA synthesis [51].”
Abdelgawad, I. A., Radwan, N. H., & Hassanein, H. R. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.12.016 · Cited by 17
Datla, S. R., Hilenski, L. L., Seidel-Rogol, B. L., Dikalova, A., Harousseau, M. E., Punkova, L., Joseph, G., Taylor, W. R., Lassegue, B. P., & Griendling, K. K. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0103-y · Cited by 18
Noda, H., Maehara, Y., Irie, K., Kakeji, Y., Yonemura, T., & Sugimachi, K. (2002) · Cancer · doi:10.1002/cncr.10417 · Cited by 17
“The C-terminal half of p21, which is involved in binding to PCNA, inhibits the potential of PCNA to activate DNA polymerase , thereby inhibiting DNA synthesis.(18,19) Thus, the loss of p21 expression may be a growth advantage to tumor cells: Previous studies correlated the loss of p21 expression with disease progressi…”
BackgroundLin, S., & Carpenter, E. J. (1998) · PubMed · Cited by 18
Thullberg, M., Welcker, M., Bártková, J., Kjerulff, A. A., Lukas, J., Johan, H. V. E., & Bartek, J. (2000) · Hybridoma · doi:10.1089/027245700315806 · Cited by 17
“…of our findings of these distinct complexes recognizable by different antibodies is that the cdks interact with p21 in unique modes, possibly through at least partly nonoverlapping sequences within the N-terminal domain of p21, (10,11) and in the vicinity of the epitopes recognized by the MAbs.”
Cell Cycle Proteins and Atherosclerosis
Zettler, M. E., & Pierce, G. N. (2000) · Herz · doi:10.1007/pl00001946 · Cited by 17
“It is believed that different regions of the p21 protein are active in inhibiting Cdks and PCNA, so the 2 mechanisms for halting the cell cycle are independent [ 38 ].”
BackgroundDNA Damage-p53/P21 Response Contributes to Ependymal Cell Development
Ortiz-Álvarez, G., Fortoul, A., Srivastava, A., Moreau, M. X., Bouloudi, B., Mailhes‐Hamon, C., Delgehyr, N., Faucourt, M., Bahin, M., Blugeon, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2022.111810 · Cited by 19
Ranta, F., Leveringhaus, J., Theilig, D. C., Schulz‐Raffelt, G., Hennige, A. M., Hildebrand, D. G., Handrick, R., Jendrossek, V., Bosch, F., Schulze‐Osthoff, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028828 · Cited by 16
“In addition to the binding to cyclin-CDK complexes, p21 interacts directly with the proliferating cell nuclear antigen (PCNA), and thereby inhibits PCNA-dependent DNA replication [51].”
BackgroundHublarová, P., Greplová, K., Holčáková, J., Vojtěšek, B., & Hrstka, R. (2010) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-010-0021-5 · Cited by 17
“p21 is a critical target protein in the response to DNA-damaging agents [38-41], and it is induced by p53-dependent and p53-independent pathways in DNA-damaged cells.”
BackgroundKhwaja, S. S., Liu, H., Tong, C., Jin, F., Pear, W. S., van Deursen, J., & Bram, R. J. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41277 · Cited by 17
Perumal, S. K., Viswanathan, M. B. G., Venkatesan, M., & Balakrishna, K. (2017) · Tumor Biology · doi:10.1177/1010428317698387 · Cited by 17
Mitra, P., Ghule, P. N., van der Deen, M., Medina, R., Xie, R.-L., Holmes, W. F., Ye, X., Nakayama, K. I., Harper, J. W., Stein, J. L., et al. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21687 · Cited by 15
“L I S S , I N C . el-Deiry et al., 1994; Luo et al., 1995; Matsuoka et al., 1995; Zhang et al., 1997, 1998, 1999; Nakayama and Nakayama, 1998; Reynaud et al., 1999; Sherr and Roberts, 1999).”
Phytoplankton Growth Studies by Cell Cycle Analysis
Carpenter, E. J., Lin, S., & Chang, J. (1998) · Springer eBooks · doi:10.1007/978-94-011-4928-0_10 · Cited by 17
The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer
Staalesen, V., Knappskog, S., Chrisanthar, R., Nord, S., Løkkevik, E., Anker, G. B., Østenstad, B., Lundgren, S., Risberg, T., Mjaaland, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2822 · Cited by 16
Use of Peptides from p21 (Waf1/Cip1) to Investigate PCNA Function in Xenopus Egg Extracts
Mattock, H., Jares, P., Zheleva, D. I., Lane, D. P., Warbrick, E., & Blow, J. J. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5181 · Cited by 16
Regulation of the cell cycle by CDK inhibitors
Soos, T. J., Park, M., Kiyokawa, H., & Koff, A. (1998) · Results and problems in cell differentiation · doi:10.1007/978-3-540-69686-5_5 · Cited by 16
Mammalian DNA repair responses and genomic instability
Rhys, C. M. J. A., & Bohr, V. A. (1996) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-9088-5_19 · Cited by 17
Induction of differentiation by wild-type p53 gene in a human glioma cell line
Kokunai, T., Kawamura, A., & Tamaki, N. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005732003296 · Cited by 17
“p21 contains an N-terminal CDK inhibitory domain that could inhibit cell cycle progression independent of the C-terminal domain [13, 15 ].”
BackgroundGomes, A., Giri, B., Kole, L., Saha, A., Debnath, A., & Gomes, A. (2007) · Toxicon · doi:10.1016/j.toxicon.2007.06.018 · Cited by 15
“The protein p21 also binds to the DNA polymerase d processivity factor, PCNA and inhibits PCNA-dependent DNA replication (Luo et al., 1995).”
Backgroundp53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma
Runnebaum, I. B., Köhler, T., Stickeler, E., Kieback, H., & Kreienberg, R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.510 · Cited by 15
Modulation of nuclear internalization of Tat peptides by fluorescent dyes and receptor‐avid peptides
Shen, D., Liang, K., Ye, Y., Tetteh, E., & Achilefu, S. A. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.03.067 · Cited by 14
Metadata
- Authors
- Luo, Y., Hurwitz, J., & Massagué, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Massagué, Joan
- Venue
- Nature
- Published
- 1995-05
- Volume
- 375
- Issue
- 6527
- Pages
- 159-161
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2030231219
- Cited by
- 549
- References
- 18
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 6 · 2018: 8 · 2017: 13 · 2016: 12 · 2015: 9 · 2014: 8 · 2013: 7 · 2012: 16
- FWCI
- 23.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p21, cyclin-dependent kinases, proliferating cell nuclear antigen, C-terminal domain, cell cycle inhibition, DNA replication inhibition, p27, p57KIP2, S phase entry
- MeSH terms
- Amino Acid Sequence, Animals, Binding Sites, Cell Cycle, DNA, Humans, Molecular Sequence Data, Recombinant Fusion Proteins, Cyclins, Protein Serine-Threonine Kinases, Proliferating Cell Nuclear Antigen, Cyclin-Dependent Kinases, CDC2-CDC28 Kinases, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase 2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.